Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Cardiovasc Drugs Ther (2017) 31:229–232 DOI 10.1007/s10557-017-6741-2 EDITORIAL Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line Editorial to: BEmpagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes^ by N. Hammoudi et al. 1 1 1 Manisha Gupte & Prachi Umbarkar & Hind Lal Published online: 21 July 2017 Springer Science+Business Media, LLC 2017 Type 2 diabetes mellitus (T2DM), which affects 29 million T2DM patients receiving empagliflozin showed significantly Americans, is a major risk factor for the development of car- reduced cardiovascular associated events. While the available diovascular diseases (CVD) such as myocardial infarction and data provide a strong evidence of empagliflozin benefits in heart failure (HF). In the last decade, empagliflozin, a sodium reducing cardiac mortality and morbidity, the mechanism through which empagliflozin exerts its cardiac benefits is un- glucose co-transporter 2 (SGLT-2) inhibitor, has emerged as a novel and promising drug for T2DM patients with benefits known. Therefore, an important challenge remaining is to elu- extending beyond its glucose-lowering action [1]. These com- cidate the molecular mechanism of empagliflozin-mediated prise weight loss, blood pressure reduction, lessening arterial cardiac benefits. stiffness, and a remarkable drop in cardiovascular death [2–5]. The study by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Drugs and Therapy Springer Journals

Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line

Loading next page...
 
/lp/springer_journal/mechanistic-insights-of-empagliflozin-mediated-cardiac-benefits-TRFW6FqI6R
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Cardiology
ISSN
0920-3206
eISSN
1573-7241
D.O.I.
10.1007/s10557-017-6741-2
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial